Pediatric Crohn’s: Switching Biologics Yields Similar Remission Rates Despite Lower Blood Drug Levels
Pediatric and adolescent Crohn’s disease patients who switch to infliximab after losing responsiveness to adalimumab display lower drug...
Search results for "infliximab"
Zymfentra U.S. Sales Surge 176% as Celltrion’s Remsima Franchise Eyes 1 Trillion Won Annual Revenue
Biopharmaceutical company Celltrion announced on Aug. 27 that combined first-half sales of its subcutaneous infliximab products—Remsima SC and...
Celltrion: “Zymfentra prescriptions surging in the U.S.… growth is accelerating in earnest”
Celltrion’s subcutaneous formulation for autoimmune diseases, “Zymfentra,” which launched in the United States, has...
Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US
Celltrion has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 4...
Celltrion Secures Dominant Market Share in Asia Led by Autoimmune and Oncology Biosimilars
Celltrion is consolidating its leading market position across major Asian countries with its key autoimmune and...
1